vs
GORMAN RUPP CO(GRC)とOrthofix Medical Inc.(OFIX)の財務データ比較。上の社名をクリックして会社を切り替えられます
Orthofix Medical Inc.の直近四半期売上が大きい($219.9M vs $166.6M、GORMAN RUPP COの約1.3倍)。GORMAN RUPP COの純利益率が高く(8.3% vs -1.0%、差は9.3%)。GORMAN RUPP COの前年同期比売上増加率が高い(2.4% vs 2.0%)。Orthofix Medical Inc.の直近四半期フリーキャッシュフローが多い($16.8M vs $10.2M)。過去8四半期でOrthofix Medical Inc.の売上複合成長率が高い(8.0% vs 2.3%)
ゴーマン・ラップはオハイオ州マンスフィールドに本拠を置くポンプメーカーです。市政給水、汚水処理、工業、建設、石油、消防、OEMなど多様な分野向けのポンプを製造しており、ニューヨーク証券取引所に上場していて、現CEOはスコット・キングです。
オーソフィックスメディカル社は世界的な整形外科医療機器メーカーで、脊椎インプラント、整形外科用外傷治療製品、骨成長刺激療法機器、再生医療製品の開発・製造・販売を事業としています。北米、欧州、アジア太平洋を中心に整形外科医や医療機関向けに製品を提供し、筋骨格系疾患患者の治療成績向上に取り組んでいます。
GRC vs OFIX — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | ||
|---|---|---|
| 売上 | $166.6M | $219.9M |
| 純利益 | $13.7M | $-2.2M |
| 粗利率 | 31.4% | 71.1% |
| 営業利益率 | 14.9% | 0.2% |
| 純利益率 | 8.3% | -1.0% |
| 売上前年比 | 2.4% | 2.0% |
| 純利益前年比 | 25.2% | 92.4% |
| EPS(希薄化後) | $0.53 | $-0.05 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $166.6M | $219.9M | ||
| Q3 25 | $172.8M | $205.6M | ||
| Q2 25 | $179.0M | $203.1M | ||
| Q1 25 | $163.9M | $193.6M | ||
| Q4 24 | $162.7M | $215.7M | ||
| Q3 24 | $168.2M | $196.6M | ||
| Q2 24 | $169.5M | $198.6M | ||
| Q1 24 | $159.3M | $188.6M |
| Q4 25 | $13.7M | $-2.2M | ||
| Q3 25 | $11.3M | $-22.8M | ||
| Q2 25 | $15.8M | $-14.1M | ||
| Q1 25 | $12.1M | $-53.1M | ||
| Q4 24 | $11.0M | $-29.1M | ||
| Q3 24 | $12.9M | $-27.4M | ||
| Q2 24 | $8.3M | $-33.4M | ||
| Q1 24 | $7.9M | $-36.0M |
| Q4 25 | 31.4% | 71.1% | ||
| Q3 25 | 29.2% | 72.2% | ||
| Q2 25 | 31.3% | 68.7% | ||
| Q1 25 | 30.7% | 62.8% | ||
| Q4 24 | 30.2% | 69.0% | ||
| Q3 24 | 31.3% | 68.7% | ||
| Q2 24 | 31.9% | 67.8% | ||
| Q1 24 | 30.4% | 67.5% |
| Q4 25 | 14.9% | 0.2% | ||
| Q3 25 | 12.4% | -8.3% | ||
| Q2 25 | 15.0% | -7.9% | ||
| Q1 25 | 13.5% | -25.2% | ||
| Q4 24 | 13.0% | -5.3% | ||
| Q3 24 | 14.2% | -9.6% | ||
| Q2 24 | 15.4% | -12.5% | ||
| Q1 24 | 12.8% | -15.6% |
| Q4 25 | 8.3% | -1.0% | ||
| Q3 25 | 6.6% | -11.1% | ||
| Q2 25 | 8.8% | -6.9% | ||
| Q1 25 | 7.4% | -27.4% | ||
| Q4 24 | 6.7% | -13.5% | ||
| Q3 24 | 7.7% | -13.9% | ||
| Q2 24 | 4.9% | -16.8% | ||
| Q1 24 | 5.0% | -19.1% |
| Q4 25 | $0.53 | $-0.05 | ||
| Q3 25 | $0.43 | $-0.57 | ||
| Q2 25 | $0.60 | $-0.36 | ||
| Q1 25 | $0.46 | $-1.35 | ||
| Q4 24 | $0.42 | $-0.76 | ||
| Q3 24 | $0.49 | $-0.71 | ||
| Q2 24 | $0.32 | $-0.88 | ||
| Q1 24 | $0.30 | $-0.95 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | ||
|---|---|---|
| 現金・短期投資手元流動性 | $35.1M | $82.0M |
| 総負債低いほど良い | $307.5M | — |
| 株主資本純資産 | $414.7M | $450.0M |
| 総資産 | $860.1M | $850.6M |
| 負債/資本比率低いほどレバレッジが低い | 0.74× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $35.1M | $82.0M | ||
| Q3 25 | $42.9M | $62.9M | ||
| Q2 25 | $27.0M | $65.6M | ||
| Q1 25 | $21.8M | $58.0M | ||
| Q4 24 | $24.2M | $83.2M | ||
| Q3 24 | $39.7M | $30.1M | ||
| Q2 24 | $34.2M | $26.4M | ||
| Q1 24 | $27.8M | $27.0M |
| Q4 25 | $307.5M | — | ||
| Q3 25 | $322.3M | $157.2M | ||
| Q2 25 | $337.1M | $157.0M | ||
| Q1 25 | $352.2M | $156.9M | ||
| Q4 24 | $366.6M | $157.0M | ||
| Q3 24 | $381.0M | $118.5M | ||
| Q2 24 | $395.4M | $118.0M | ||
| Q1 24 | $400.7M | $118.2M |
| Q4 25 | $414.7M | $450.0M | ||
| Q3 25 | $405.2M | $442.5M | ||
| Q2 25 | $397.8M | $458.3M | ||
| Q1 25 | $382.1M | $458.3M | ||
| Q4 24 | $373.8M | $503.1M | ||
| Q3 24 | $367.3M | $525.9M | ||
| Q2 24 | $358.6M | $546.0M | ||
| Q1 24 | $353.7M | $570.3M |
| Q4 25 | $860.1M | $850.6M | ||
| Q3 25 | $869.9M | $832.6M | ||
| Q2 25 | $861.8M | $837.2M | ||
| Q1 25 | $857.8M | $823.1M | ||
| Q4 24 | $858.5M | $893.3M | ||
| Q3 24 | $883.5M | $867.9M | ||
| Q2 24 | $891.1M | $882.0M | ||
| Q1 24 | $887.4M | $906.0M |
| Q4 25 | 0.74× | — | ||
| Q3 25 | 0.80× | 0.36× | ||
| Q2 25 | 0.85× | 0.34× | ||
| Q1 25 | 0.92× | 0.34× | ||
| Q4 24 | 0.98× | 0.31× | ||
| Q3 24 | 1.04× | 0.23× | ||
| Q2 24 | 1.10× | 0.22× | ||
| Q1 24 | 1.13× | 0.21× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | ||
|---|---|---|
| 営業キャッシュフロー直近四半期 | $15.0M | $27.7M |
| フリーキャッシュフロー営業CF - 設備投資 | $10.2M | $16.8M |
| FCFマージンFCF / 売上 | 6.1% | 7.6% |
| 設備投資強度設備投資 / 売上 | 2.9% | 4.9% |
| キャッシュ転換率営業CF / 純利益 | 1.09× | — |
| 直近12ヶ月FCF直近4四半期 | $88.9M | $-1.3M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $15.0M | $27.7M | ||
| Q3 25 | $42.3M | $12.4M | ||
| Q2 25 | $27.8M | $11.6M | ||
| Q1 25 | $21.1M | $-18.4M | ||
| Q4 24 | $9.3M | $23.7M | ||
| Q3 24 | $27.2M | $11.7M | ||
| Q2 24 | $22.7M | $9.0M | ||
| Q1 24 | $10.7M | $-18.6M |
| Q4 25 | $10.2M | $16.8M | ||
| Q3 25 | $35.8M | $2.5M | ||
| Q2 25 | $24.8M | $4.5M | ||
| Q1 25 | $18.1M | $-25.1M | ||
| Q4 24 | $5.2M | $15.2M | ||
| Q3 24 | $24.0M | $6.3M | ||
| Q2 24 | $19.4M | $-360.0K | ||
| Q1 24 | $6.8M | $-29.1M |
| Q4 25 | 6.1% | 7.6% | ||
| Q3 25 | 20.7% | 1.2% | ||
| Q2 25 | 13.9% | 2.2% | ||
| Q1 25 | 11.0% | -13.0% | ||
| Q4 24 | 3.2% | 7.0% | ||
| Q3 24 | 14.3% | 3.2% | ||
| Q2 24 | 11.5% | -0.2% | ||
| Q1 24 | 4.3% | -15.4% |
| Q4 25 | 2.9% | 4.9% | ||
| Q3 25 | 3.8% | 4.8% | ||
| Q2 25 | 1.7% | 3.5% | ||
| Q1 25 | 1.8% | 3.5% | ||
| Q4 24 | 2.5% | 4.0% | ||
| Q3 24 | 1.9% | 2.7% | ||
| Q2 24 | 1.9% | 4.7% | ||
| Q1 24 | 2.5% | 5.6% |
| Q4 25 | 1.09× | — | ||
| Q3 25 | 3.73× | — | ||
| Q2 25 | 1.76× | — | ||
| Q1 25 | 1.74× | — | ||
| Q4 24 | 0.84× | — | ||
| Q3 24 | 2.10× | — | ||
| Q2 24 | 2.72× | — | ||
| Q1 24 | 1.36× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
GRC
| Industrial | $34.7M | 21% |
| Fire Market | $31.4M | 19% |
| Municipal | $25.3M | 15% |
| Agriculture | $22.5M | 14% |
| Repair Parts | $18.9M | 11% |
| Construction | $17.3M | 10% |
| Original Equipment Manufacturer | $10.8M | 7% |
| Petroleum | $5.6M | 3% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |